AtriCure (ATRC) reported $140.5 million in revenue for the quarter ended December 2025, representing a year-over-year increase of 13.1%. EPS of $0.06 for the same period compares to -$0.08 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $140.49 million, representing a surprise of +0.01%. The company delivered an EPS surprise of +400%, with the consensus EPS estimate being -$0.02.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how AtriCure performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- United States Revenue- Pain management: $22.65 million versus the three-analyst average estimate of $21.64 million. The reported number represents a year-over-year change of +27.3%.
- International Revenue- Pain management: $1.79 million compared to the $2.55 million average estimate based on three analysts. The reported number represents a change of -3.6% year over year.
- United States Revenue- Total: $114.33 million versus $113.62 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +12.6% change.
- International Revenue- Total: $26.17 million compared to the $26.53 million average estimate based on three analysts. The reported number represents a change of +15.3% year over year.
- United States Revenue- Total ablation ( Open ablation+Minimally invasive ablation+Pain management): $68.86 million versus the three-analyst average estimate of $66.62 million. The reported number represents a year-over-year change of +12.4%.
- International Revenue- Minimally invasive ablation: $2.12 million compared to the $2.68 million average estimate based on three analysts. The reported number represents a change of -16.5% year over year.
- United States Revenue- Appendage management: $45.48 million versus the three-analyst average estimate of $47.01 million. The reported number represents a year-over-year change of +12.8%.
- International Revenue- Appendage management: $11.41 million compared to the $10.86 million average estimate based on three analysts. The reported number represents a change of +22.9% year over year.
- United States Revenue- Open ablation: $38.48 million versus $37.29 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +16.7% change.
- International Revenue- Open ablation: $10.84 million compared to the $10.44 million average estimate based on three analysts. The reported number represents a change of +20.3% year over year.
- United States Revenue- Minimally invasive ablation: $7.73 million compared to the $7.68 million average estimate based on three analysts. The reported number represents a change of -26.2% year over year.
- International Revenue- Total ablation ( Open ablation+Minimally invasive ablation+Pain management): $14.76 million versus the three-analyst average estimate of $15.67 million. The reported number represents a year-over-year change of +10%.
View all Key Company Metrics for AtriCure here>>>
Shares of AtriCure have returned -16.4% over the past month versus the Zacks S&P 500 composite's -1.4% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
AtriCure, Inc. (ATRC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
